Free Trial

LLA.L,0P0001T9GN,0 (LLA) Competitors

GBX 15 0.00 (0.00%)
(As of 11/20/2024 09:21 PM ET)

LLA vs. DXRX, AGL, YGEN, ABDX, GDR, VRCI, PRM, GENI, LLAI, and IDHC

Should you be buying LLA.L,0P0001T9GN,0 stock or one of its competitors? The main competitors of LLA.L,0P0001T9GN,0 include Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), genedrive (GDR), Verici Dx (VRCI), Proteome Sciences (PRM), GENinCode (GENI), LungLife AI (LLAI), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.

LLA.L,0P0001T9GN,0 vs.

LLA.L,0P0001T9GN,0 (LON:LLA) and Diaceutics (LON:DXRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, LLA.L,0P0001T9GN,0's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company Overall Sentiment
LLA.L,0P0001T9GN,0 Neutral
Diaceutics Neutral

5.4% of LLA.L,0P0001T9GN,0 shares are owned by institutional investors. Comparatively, 52.4% of Diaceutics shares are owned by institutional investors. 34.3% of Diaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Diaceutics has higher revenue and earnings than LLA.L,0P0001T9GN,0. Diaceutics is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LLA.L,0P0001T9GN,0N/AN/A-£4.47M-£0.12-125.00
Diaceutics£26.09M3.79-£2.85M-£0.03-3,903.33

LLA.L,0P0001T9GN,0 has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Diaceutics received 12 more outperform votes than LLA.L,0P0001T9GN,0 when rated by MarketBeat users.

CompanyUnderperformOutperform
LLA.L,0P0001T9GN,0N/AN/A
DiaceuticsOutperform Votes
12
85.71%
Underperform Votes
2
14.29%

LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to Diaceutics' net margin of -10.90%. Diaceutics' return on equity of -7.13% beat LLA.L,0P0001T9GN,0's return on equity.

Company Net Margins Return on Equity Return on Assets
LLA.L,0P0001T9GN,0N/A -48.59% -27.28%
Diaceutics -10.90%-7.13%-6.06%

Diaceutics has a consensus price target of GBX 160, indicating a potential upside of 36.64%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than LLA.L,0P0001T9GN,0.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LLA.L,0P0001T9GN,0
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Diaceutics beats LLA.L,0P0001T9GN,0 on 12 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLA vs. The Competition

MetricLLA.L,0P0001T9GN,0Diagnostics & Research IndustryMedical SectorLON Exchange
Market CapN/A£26.49M£5.09B£1.39B
Dividend YieldN/A5.44%5.04%11.75%
P/E Ratio-125.001.9193.091,551.07
Price / SalesN/A2,197.801,220.67209,494.22
Price / CashN/A9.9539.4932.97
Price / Book0.542.336.932.81
Net Income-£4.47M£45.44M£118.83M£152.70M
7 Day PerformanceN/A1.79%-1.74%-0.48%
1 Month PerformanceN/A-3.75%-3.60%7.15%
1 Year PerformanceN/A4.51%31.91%93.19%

LLA.L,0P0001T9GN,0 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLA
LLA.L,0P0001T9GN,0
N/AGBX 15
flat
N/AN/A£0.00N/A-125.0015High Trading Volume
DXRX
Diaceutics
N/AGBX 117.10
-1.2%
GBX 160
+36.6%
+32.6%£98.91M£26.09M-3,933.33151
AGL
ANGLE
1.2384 of 5 stars
GBX 11
-4.3%
GBX 70
+536.4%
+9.5%£35.48M£2.02M-157.14650
YGEN
Yourgene Health
N/AGBX 0.52
flat
N/A+0.0%£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 7.25
flat
N/A-32.5%£13.74M£6.13M-899.0084News Coverage
GDR
genedrive
N/AGBX 2.45
+2.1%
N/A-66.9%£13.31M£49,000.00-60.0043
VRCI
Verici Dx
N/AGBX 3.38
flat
N/A-65.7%£8.19M£4.33M-168.7519
PRM
Proteome Sciences
N/AGBX 2.75
flat
N/A-54.2%£8.12M£4.04M-230.00240Gap Down
GENI
GENinCode
N/AGBX 4.15
flat
N/A-44.0%£7.34M£2.60M-83.602,300Gap Down
LLAI
LungLife AI
N/AGBX 8.75
flat
N/A-90.7%£2.68M£98,566.00-67.3115
IDHC
Integrated Diagnostics
N/AGBX 0.38
-2.6%
N/A+18.2%£2.21M£4.75B12.336,692Gap Down

Related Companies and Tools


This page (LON:LLA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners